title: Atazanavir induced first degree atrioventricular block and ventricular tachycardia: a case report.
abstract: Atazanavir is one highly active antiretroviral therapy for naïve patients or patients with previous regimen failure. However, it seems that the protease inhibitor induces hyperlipidemia. Hyperbillirubinemia is the most common clinical adverse events but reports of cardiotoxicity due to atazanavir are scarce. The authors report a patient who had QT prolongation, first-degree atrioventricularblock, and ventricular tachycardia. After atazanavir/ritonavir discontinuation, this patient got better and had normal electrocardiography. Lopinavir/ritonavir was carefully reintroduced during hospitalization without any adverse drug reaction. Atazanavir induced cardiotoxicity has to be monitored when using protease inhibitors.
authors.affiliation: Department of Pharmacy, Faculty of Pharmacy, Silapakorn University, Nakornpathom, Thailand.
authors.forename: Wichai
authors.initials: W
authors.lastname: Santimaleeworagun
authors.forename: Suthipom
authors.initials: S
authors.lastname: Pattharachayakul
authors.forename: Sarunyou
authors.initials: S
authors.lastname: Chusri
authors.forename: Pantip
authors.initials: P
authors.lastname: Chayagul
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D000069446:Atazanavir Sulfate; D054537:Atrioventricular Block / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D017180:Tachycardia, Ventricular / Q000139:chemically induced*
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate